Credit Suisse Downgrades Myriad Genetics (MYGN) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
JMP Securities Upgrades Myriad Genetics (MYGN) to Market Outperform
February 4, 2015 7:08 AM ESTJMP Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Market Outperform with a price target of $50.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $38.12 yesterday.
... MoreMizuho Securities Downgrades Myriad Genetics (MYGN) to Neutral
February 4, 2015 7:07 AM ESTMizuho Securities downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Neutral with a price target of $32.00 (from $50.00).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $38.12 yesterday.
... MoreMyriad Genetics (MYGN) CEO to Retire
February 3, 2015 4:11 PM ESTMyriad Genetics, Inc. (Nasdaq: MYGN) today announced that Peter D. Meldrum, president and chief executive officer, has notified the company of his decision to retire at the conclusion of the fiscal year on June 30, 2015. Pursuant to the company's succession plan, the board of directors has unanimously elected Mark C. Capone, currently president of Myriad Genetic Laboratories, Inc., as Mr. Meldrum's successor. Mr. Capone, a 13-year veteran of the company, has worked closely with Mr. Meldrum and the board in charting the strategic direction and managing the overall business of the company, as well as regularly... More
Myriad Genetics (MYGN) Tops Q2 EPS by 5c; Cuts FY15 Outlook
February 3, 2015 4:08 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $184.4 million versus the consensus estimate of $183.41 million.
Myriad Genetics sees FY2015 EPS of $1.50 - $1.55, versus the consensus of $1.85. Myriad Genetics sees FY2015... More
